Skip Navigation

Research Funding

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Small Business High-Priority Areas of Interest

NIAID's divisions are particularly interested in applications that address the areas listed below. Also read NIAID's section of the NIH Omnibus Solicitation for SBIR and STTR Grant Applications.

Note that NIAID does not support clinical trials through the SBIR or STTR programs, with the exception of our NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44). For details, read "Can my small business obtain funding for a clinical trial?"

Scroll or click down to DAIDS, DAIT, or DMID.

Division of AIDS—Small Business High-Priority Areas of Interest

Updated March 28, 2013.

Areas of Interest Subject Matter Expert Email Phone
Preclinical development and evaluation of HIV vaccines, adjuvants and delivery systems in animal models using SIV, SHIV, or HIV. Vaccines that enhance innate and mucosal immunities and induce broadly reactive and long lasting neutralizing antibodies are program priorities. Novel technologies (e.g., nanotechnology) and vaccine vectors are also priority areas of research interests. Yen Li 301-496-3816
Development of anti-HIV agents directed at new viral or cellular targets. Brigitte Sanders 301-496-6714
Development of novel anti-HIV drugs and therapeutics with focus on technological aspects such as multiplex analysis of drugs and innovative, streamlined methods for drug screening and drug delivery (e.g., multifunctional therapeutics based on nanotechnology). Development of bio-assay and bio-imaging applications for the assessment of HIV pathogenesis. Kailash Gupta 301-435-3724
Preclinical development of single and combination non-vaccine biomedical prevention candidates (topical microbicides, PrEP and Multipurpose Prevention Technologies (MPT)) which prevent the transmission of HIV in the genital and gastrointestinal tracts of men and women; Development of oral, injectable, implantable and topical sustained delivery strategies for topical microbicides, PrEP and MPT; creation and advancement of new technologies, targets, and approaches, including nanotechnology, which promote the safety, efficacy, adherence and acceptability of non-vaccine biomedical prevention candidates and strategies. Jim A. Turpin 301-451-2732
Development, standardization, validation and evaluation of improved technologies to detect HIV, to evaluate immune responses to HIV vaccines and to vaccine vectors, or to correlate immune responses associated with vaccine efficacy. Thandi Onami 301-594-1321
Development and evaluation of practical and affordable tests to measure viral load, CD4+ cell counts, and drug toxicities and drug resistance to monitor populations in resource-poor settings. Development of tests to detect early infection in seropositive HIV-infected individuals. Michael Ussery 301-402-0134
Development of novel, non-sputum-based methods for the diagnosis of active and latent TB infection in HIV-positive or HIV-negative infants and children. Marco Schito, Contractor, Henry M. Jackson Foundation 301-594-5374
Preclinical discovery and development of antimicrobial agents directed against Mycobacterium avium, Pneumocystis pneumonia, and Cryptococcus neoformans (and other pathogenic fungi). Development and delivery of nanotechnology-based therapeutics to target pathogen or pathogen-infected cells. Influence of antiretrovirals (e.g., ritonavir) on antimicrobial efficacy. Chris Lambros 301-435-3769
Preclinical development and evaluation of therapeutic vaccines and other immune-based therapies to attenuate HIV disease progression or reduce HIV infectiousness. Tony Conley 301-451-2739
Development of gene therapies for HIV. Frosso Voulgaropoulou 301-451-2704
Research to assess and overcome specific biomedical obstacles in HIV vaccine discovery, especially by application of novel technology to vaccine discovery and/or by the development and supply of novel reagents and other resources useful in novel vaccine discovery. Stuart Shapiro 301-402-0122
Discovery and development of agents or strategies for Pre-exposure prophylaxis (PrEP) (single or multiple agents, immunological, pharmacological, or other potential approaches directed against viral and/or host targets). Development of pharmacological tools to examine PK/PD in fluids and tissue, new formulation and delivery systems (including nanotechnology-based approaches) for coitally-dissociated use, and optimization of animal models for screening of candidate agents. David Burns 301-435-8896

Development of formulation strategies to deliver antiretrovirals to specific target cells or tissues.  Development of sustained release formulations to be delivered by oral, injectable, implantable, or transdermal routes of administration for treatment of HIV infection.

Steve Turk 301-435-3771
Development of novel and improved assays for the determination of HIV incidence. These diagnostic assays should identify HIV infection before seroconversion, be based on B and non-B subtypes, and include the development, incorporation, and validation of process controls. Usha Sharma 301-451-3441

Development of rapid tests for the detection of ARTs in various human matrices (e.g. blood, urine, hair). The assay should require minimal operator effort and expertise, and include the development, incorporation, and validation of process controls.

Hao Zhang


Division of Allergy, Immunology, and Transplantation—Small Business High-Priority Areas of Interest

Updated February 28, 2013.

Areas of Interest Contact Email Phone
Development of novel vaccine adjuvants. Helen Quill


Development of medical countermeasures to protect against, mitigate, and treat the short- and long-term effects of radiation exposure due to terrorist attack.

Andrea DiCarlo-Cohen


Development of novel or improved decorporation agents to remove radionuclides from the body following accidental inhalation, ingestion or wound entry.

David Cassatt


Identification of radiation exposure biomarkers and development of new biodosimetry methods and devices for triage of radiation-exposed people.

Francesca Macchiarini


Novel approaches for detecting infants at risk for developing asthma and other allergic diseases.

Alkis Togias


Immune targets for asthma and allergic disease interventions. Development of immunotherapies to prevent or treat allergic diseases.

Marshall Plaut


Single cell assays to isolate and study allergen-specific lymphocytes.

Gang Dong


Development of new reagents and non-murine animal models for allergy research.

Michael Minnicozzi


Innovative treatments for autoimmune diseases.

John Peyman


Biomarkers to measure risk, disease activity, and therapeutic response in autoimmune diseases. 

Thomas Esch


High throughput assay of T-cell activity in autoimmune diseases.

Katarzyna Bourcier


Mucosal immunity. 

Annette Rothermel


Standardized validated diagnostic criteria and outcome measures for autoimmune diseases correlated with disease activity.

David Johnson


Immunotherapeutic antibodies.

Helen Quill


Biomarkers of host immune defense.

Helen Quill


Single cell and other sample-sparing assays for study of human immunology.

Helen Quill


Methods and analysis tools to facilitate high throughput, high resolution MHC typing in humans and non-human primates.

Kristy Kraemer


Immunomodulatory agents to prevent graft rejection and biomarkers to predict transplantation outcomes.

Nancy Bridges


Division of Microbiology and Infectious Diseases—Small Business High-Priority Areas of Interest

Updated February 3, 2012.

Areas of Interest Contact Email Phone

Identify and qualify infectious disease-related biomarkers, including:

  • Biomarkers to predict susceptibility to infection.
  • Biomarkers to diagnose an infectious disease.
  • Biomarkers to predict or monitor a subject’s response to a therapeutic, including efficacy and toxicity biomarkers.
  • Biomarkers to predict or monitor a subject’s response to vaccination.
  • Biomarkers to determine the possibility of infection mediated by insect vectors.
  • Biomarkers from natural history studies that could be used to assess disease progression in acute and chronic diseases.
Barbara Mulach 301-496-1884

Development of more sensitive and accurate methods of direct detection of Borrelia burgdorferi for the purpose of diagnosing Lyme disease patients. Diagnostic approaches that contain one or more of the following are also encouraged: substantial and significant advances over conventional antibody-based approaches, methods that take into account host response, ability to detect and differentiate multiple strains of Borrelia burgdorferi, and discriminate between active and previous infection.

Barbara Mulach 301-496-1884

Vaccines for NIAID Category A, B, and C priority pathogens including influenza, Ebola, Marburg, arenavirus, and other viral encephalitides.

Barbara Mulach 301-496-1884

Vaccine development for tuberculosis, STIs, hepatitis B and C, and malaria and other high-impact global parasitic diseases.

Barbara Mulach 301-496-1884

Vaccine enhancement and formulation technologies with the goal of providing protection against multiple infectious disease agents, providing accelerated immune responses (more rapid schedules or reduced number of immunizations), increase ease of administration (i.e., self-administration), and increase product stability to minimize cold chain requirements.

Barbara Mulach 301-496-1884

Therapeutics for NIAID Category A, B, and C priority pathogens including smallpox, viral hemorrhagic fevers, viral encephalitides, botulinum neurotoxins, and influenza.

Barbara Mulach 301-496-1884

Therapeutics for tuberculosis, hepatitis B and C, and malaria and other high-impact global parasitic diseases.

Barbara Mulach 301-496-1884

Therapeutics exhibiting broad-spectrum activity against microbial pathogens.

Barbara Mulach 301-496-1884

Therapeutic enhancement and formulation technologies with the goal of improving drug development timeframes, productivity, efficacy, specificity, safety, stability, and delivery.

Barbara Mulach 301-496-1884

Development of simple, rapid, field-deployable, sensitive, and specific point-of-care in vitro diagnostics for:

  • NIAID Category A, B, and C priority pathogens and those causing emerging and re-emerging infectious diseases.
  • Respiratory disease pathogens including tuberculosis, community acquired pneumonia, and influenza, including emerging and re-emerging influenza viruses such as 2009 H1N1 influenza.
  • Sexually transmitted infections, especially those affecting women with limited access to health care. These organisms include but are not limited to Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Group B streptococcus.
  • Differentiating among causes of acute febrile illness in tropical and subtropical regions, including bacterial infections and malaria and other high-impact, global parasitic diseases.
  • Detection of infectious disease-causing pathogens (bacteria, viral, or parasite) and determination of their antimicrobial resistance and/or sensitivity profiles.
Barbara Mulach 301-496-1884

Development of next generation sequencing and genomic technologies for new diagnostic strategies for infectious diseases including molecular signatures developed from studies on human microbiome and pathogen-host interactions.

Barbara Mulach 301-496-1884
Vaccines, therapeutics, and diagnostics for emerging and re-emerging influenza viruses such as 2009 H1N1 influenza. Barbara Mulach 301-496-1884

Last Updated July 26, 2013

Last Reviewed March 28, 2013